3 Reasons Why You Should Sell Shire PLC

Shire PLC (LON:SHP) shareholders should heed the lessons of Pfizer’s bid for AstraZeneca plc (LON:AZN), says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shireShire (LSE: SHP) (NASDAQOTH: SHPG.US) shareholders have seen the value of their stock rise by 60% this year, thanks mainly to a takeover bid from US firm AbbVie.

However, Shire’s management is currently playing hardball, by claiming that the bid “fundamentally undervalues the company and its prospects”.

If you’re a Shire shareholder, you may think that the correct approach is to sit tight and wait for AbbVie to make a higher offer — and they might. However, I’m not sure the figures support a higher bid.

1. Isn’t Shire worth more?

The main claim made by Shire’s board to justify a higher valuation is that Shire’s sales will double to $10bn by 2020.

Assuming the firm maintains its historic post-tax profit margin of around 17%, this means that net income could rise to around $1.7bn by 2020. If we generously round this up to $2.5bn to allow for acquisitions, then Shire’s current share price equates to a 2020 forecast P/E of almost 18!

I reckon that’s a very generous valuation indeed.

2. Are you a gambler?

AstraZeneca‘s (LSE: AZN) (NYSE: AZN.US) share price fell by 11% in one day after the Pfizer bid fell through.

The failure of the bid disappointed a lot of AstraZeneca investors, but as I wrote at the time, they really only had themselves to blame: if they wanted cash, they should have sold.

Waiting for a higher offer is a big gamble: one of the key principles of successful investing, in my view, is always to leave something on the table for the next person.

I mention all of this because I suspect that the same thing could happen with the current Shire bid — except here, the potential downside, post-bid, is much greater than it was with AstraZeneca:

Valuation before bid AstraZeneca Shire
2014 forecast P/E 15.2 17.9
Prospective yield 4.5% 0.5%
Peak valuation during bid    
2014 forecast P/E 19.2 23.4
Prospective yield 3.5% 0.4%

Source: Reuters analysts’ consensus forecasts

Shire has been touted as a bid target for years — but now that a decent bid has appeared, shareholders might not be so patient in the future, if this bid is allowed to fall through.

Shire’s yield is virtually zero, so the only reason to hold the stock is for capital gains. In my view, Shire’s share price could fall dramatically if the firm’s board allows this bid to fall through.

3. You should sell

Shire’s share price is 4,579p as I write, only fractionally below the 4,611p value of AbbVie’s bid.

In my view, selling carries much less risk than continuing to hold, and is the only sensible decision for most shareholders.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in Shire.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Down 21% and yielding 10%, is this income stock a top contrarian buy now?

Despite its falling share price, this Fool reckons he's found an income stock that could be worth taking a closer…

Read more »

Investing Articles

The Meta share price falls 10% on weak Q2 guidance — should investors consider buying?

The Meta Platforms' share price is down 10% after the company reported Q1 earnings per share growth of 117%. Does…

Read more »

Investing Articles

This FTSE 250 defence stock looks like a hidden growth gem to me

With countries hiking defence spending as the world grows more insecure, this FTSE 250 firm has seen surging orders and…

Read more »

Bronze bull and bear figurines
Investing Articles

1 hidden dividend superstar I’d buy over Lloyds shares right now

My stock screener flagged that I should sell my Lloyds shares and buy more Phoenix Group Holdings for three key…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

A solid track record and 5.4% yield, this is my top dividend stock pick for May

A great dividend stock is about more than its yield. When hunting for dividend heroes, I look at several metrics…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£8k in savings? Here’s how I’d aim to retire with an annual passive income of £30,000

Getting old needn't be a struggle. Even with a small pot of savings, it's possible to build up a decent…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Down 50% in a year! Are the FTSE’s 2 worst performers the best shares to buy today?

Harvey Jones is looking for the best shares to buy for his portfolio today and wonders whether these two FTSE…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is FTSE 8,000+ the turning point for UK shares?

On Tuesday 23 April, the FTSE 100 hit a new record high, in a St George's Day celebration. But I…

Read more »